Cargando…
Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study
BACKGROUND: Anaemia is common in patients with chronic kidney disease (CKD) and can be managed by therapy with erythropoiesis-stimulating agents (ESAs). Epoetin delta (DYNEPO(®), Shire plc) is the only epoetin produced in a human cell line. The aim of this study was to demonstrate the safety and eff...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664800/ https://www.ncbi.nlm.nih.gov/pubmed/19243619 http://dx.doi.org/10.1186/1471-2369-10-5 |